Liquidia (LQDA) is a US-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of $7.6B, trading at $85.76 on the NASDAQ. This SniperIQ fundamentals page covers Liquidia's valuation (P/E 358.7x, P/B 69.5x), profitability (net margin 7.7%), revenue (
58M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap$7.6B
P/E (TTM)358.7x
Net Margin7.7%
Revenue (FY25)
58M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Liquidia's market cap?
Liquidia (LQDA) has a market capitalization of approximately $7.6B, trading at $85.76 on the NASDAQ. Market cap moves with the live share price.
What is Liquidia's P/E ratio?
Liquidia's trailing twelve-month P/E ratio is 358.7x, with a price-to-book (P/B) of 69.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Liquidia?
Liquidia runs a net profit margin of 7.7%, a gross margin of 91.8%, and an operating margin of 15.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Liquidia generate?
Liquidia reported revenue of
58M for fiscal year 2025, with net income of -$69M and earnings per share (EPS) of -0.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Liquidia pay a dividend?
Liquidia does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Liquidia financially healthy?
Liquidia carries a debt-to-equity ratio of 1.70x and a current ratio of 2.22x, with a market beta of 0.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Liquidia a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Liquidia (LQDA) the key facts are: market cap $7.6B, P/E 358.7x, revenue
58M, 52-week range 16.51-89.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Liquidia's full fundamentals live
Get Liquidia's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.